Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  clofarabine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 72 for your search:
Start Over
A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLO34100405, 2008-001043-19, NCT00317642
A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 1 to 21
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLO21800205, NCT00315705
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 1 to 30
Sponsor: NCI, Other
Protocol IDs: AAML0523, CDR0000494654, NCI-2009-00319, COG-AAML0523, NCT00372619
Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 2 and over
Sponsor: NCI, Other
Protocol IDs: 06-065, P30CA008748, MSKCC-06065, NCT00416351
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Under 55
Sponsor: NCI, Other
Protocol IDs: 06-125, MSKCC-06125, NCT00423514
Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 21 and over
Sponsor: Other
Protocol IDs: 2005-0552, NCT00412243
Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 30 and under
Sponsor: Other
Protocol IDs: L 9471, NCT00529360
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 60 and under
Sponsor: Other
Protocol IDs: UMCC 2007.055, NCT00556452
Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: 6562, NCI-2009-01464, UWCC-6562, FHCRC- 6562, UWCC-UW 6562, UWCC-07-9655-H/A, NCT00602225
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 07-401, NCT00644189
Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: HCI26135, NCT00708721
Clofarabine and Cytarabine in Treating Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes That Have Relapsed or Not Responded to Treatment
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 60 and over
Sponsor: NCI, Other
Protocol IDs: 2302.00, NCI-2010-00039, P30CA015704, FHCRC-2302.00, IR-6853, NCT00839982
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: 14341B, NCT00943592
Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 16 to 120
Sponsor: Other
Protocol IDs: 090331, NCT00983528
Clofarabine in High Risk Myelodysplastic Syndrome (MDS)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: GFM-CLO-08, NCT01063257
Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: Other
Protocol IDs: 2009-0536, NCI-2012-01786, NCT01160354
A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Over 60
Sponsor: Other
Protocol IDs: SPON 845-10, 2010-021444-18, 10/MRE09/27, NCT01236144
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Phase: Phase II
Type: Treatment
Status: Completed
Age: 50 to 74
Sponsor: Other
Protocol IDs: ID03-0139, NCT00065143
Clofarabine Combinations in Relapsed/Refractory AML, MDS and Myeloid Blast Phase CML
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: ID03-0181, NCT00067028
Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).
Phase: Phase II
Type: Treatment
Status: Completed
Age: 60 and over
Sponsor: Other
Protocol IDs: 2004-0183, NCT00088218
A Phase II Study of Clofarabine in Patients With Aggressive Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: OSU-0442, NCT00201669
Oral Clofarabine Study in Patients With Myelodysplastic Syndrome
Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: 2005-0536, NCT00299156
S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI, Other
Protocol IDs: S0530, U10CA032102, SWOG-S0530, NCT00337168
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 004-145, NCT00334074
Start Over